Abstract
The aim of the study was to evaluate the efficacy and tolerability of synbiotic [BifilacTM hp] capsules as add on therapy in minimal hepatic encephalopathy [MHE] patients as assessed by cognitive state, serum ammonia level and liver function test. 60 subjects aged between 20 and 50 years were enrolled and randomized into two groups. One group received standard therapy alone and the other group received synbiotic [BifilacTM hp] along with standard therapy. The subjects were assessed using cognitive tests and blood investigation reports. Synbiotic [BifilacTM hp] therapy group showed statistically significant decrease in time needed to complete both the cognitive assessment tests i.e., Number Connection Test [NCT] and Line Tracing Test [LTT] when compared to the standard treatment group. Significant reduction in serum ammonia and hepatic enzymes level were also observed. BifilacTM hp when added to standard therapy is found to be more beneficial than the standard therapy alone in the management of minimal hepatic encephalopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Pharmaceutical Sciences and Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
